抗肿瘤靶向药品不良反应主动监测分析

doi:10.19803/j.1672-8629.2021.04.16

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (4): 368-372.
DOI: 10.19803/j.1672-8629.2021.04.16

抗肿瘤靶向药品不良反应主动监测分析

蔡萌, 李民, 沈爱宗^*

中国科学技术大学附属第一医院,安徽省立医院,安徽合肥 230001

收稿日期:2019-12-10 出版日期:2021-04-15 发布日期:2021-04-23
通讯作者: ^*沈爱宗,男,硕士,主任药师,药事管理。E-mail：1649441800@qq.com
作者简介:蔡萌,女,本科,中药学。
基金资助:
2020年度重大新药创制科技重大专项2020年度(2020ZX09201004-007)

Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs

CAI Meng, LI Min, SHEN Aizong^*

The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei Anhui 230001, China

Received:2019-12-10 Online:2021-04-15 Published:2021-04-23

摘要/Abstract

摘要： 目的对抗肿瘤靶向药品不良反应（ADR）发生的规律及特点进行分析,旨在为临床合理使用提供参考。方法通过中国医院药物警戒系统（CHPS）,主动监测某三甲医院2016年5月5日至2019年2月19日的120例住院病例,使用Excel软件,分析使用抗肿瘤靶向药物致ADR的情况。结果靶向药物致ADR共120例,患者年龄主要集中在61~70岁（33.33%）;靶向药物致ADR累及系统-器官以消化系统为主（27.32%）;临床表现主要为胃肠道反应。结论临床使用靶向药物应密切关注其ADR,治疗过程中应做好预防和预后方案,密切关注患者治疗前后的生化指标,确保用药安全。

关键词: 靶向药物, 药品不良反应, 主动监测

Abstract: Objective To analyze the occurrence and characteristics of anti-tumor targeted drug adverse reactions (ADR), so as to provide reference for rational clinical use. Methods Through the results of active monitoring of China Hospital Pharmacovigilance System (CHPS), 120 inpatient medical records from A triple-A hospital’s May 5, 2016 to February 19, 2019 were extracted, and Excel software was used to analyze the ADR caused by anti-tumor targeted drugs. Results There were 120 cases of ADR induced by targeted drugs, the patients were mainly concentrated in 61~70 years (33.33%), and the ADR involved in the target drug was mainly in the digestive system (29.81%). the clinical manifestations were mainly gastrointestinal reactions. Conclusion The clinical use of targeted drugs should pay close attention to the adverse reactions of targeted drugs, in the course of treatment should do a good job of prevention and prognosis, pay close attention to the biochemical indicators before and after treatment, to ensure the safety of drug use.

Key words: targeted drugs, adverse drug reactions, active monitoring

中图分类号:

R969.3

蔡萌, 李民, 沈爱宗. 抗肿瘤靶向药品不良反应主动监测分析[J]. 中国药物警戒, 2021, 18(4): 368-372.

CAI Meng, LI Min, SHEN Aizong. Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 368-372.

参考文献

[1] Germany Boehringer Ingelheim Pharma GmbH & Co. KG. Description of afatinib dimaleate capsule[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/smshb20190415/199.pdf.
[2] Jiangsu Hengrui Medicine Co., Ltd. Description of apatinib mesylate tablets[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/sms20180413/54.pdf.
[3] Roche Pharma(Switzerland)Ltd. Description of bevacizumab injection [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/20180711 sms/133.pdf.
[4] Roche Registration Ltd. Description of Tarceva(Erlotinib Hydrochloride Tablets) [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a230.pdf.
[5] Astra Zeneca UK Limited. Description of Gefitinib Tablets[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/344.pdf.
[6] Roche Pharma (Schweiz)AG. Description of rituximab injection[EB/OL].[2019-04-23]. https://db.yaozh.com/instruct/103643.html.
[7] BSP Pharmaceuticals S.r.l. Description of Bortezomib for Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ypsms151012/34.pdf.
[8] Roche Pharma (Schweiz) Ltd. Description of Trastuzumab Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a468.pdf.
[9] Merck KGaA. Description of Cetuximab Solution for Infusion[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/2086.pdf.
[10] Takeda Pharma A/S. Description of Ixazomib Citrate Capsules [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/FDA/28.pdf.
[11] National Center for ADR Monitoring, State food and drug administration drug evaluation center. WHOART (WHO药品不良反应术语集)[M]. Beijing: China Medical Science and Technology Press, 2002:1-172.
[12] Wang D.Active surveillance of adverse drug reaction and Its development trend[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) ,2015,12(10):600-602.
[13] National Center for ADR Monitoring. The National center held a ceremony to award the national ADR monitoring outpost [EB/OL]. (2017-12-14)[2018-06-20]. http://www.cdr-adr.org.cn/xwdt/ 201712/ t20171214 19834. html.
[14] Bass JM,Krens LL,Guchelaar HJ,et al.Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review[J]. Cancer Treatment Reviews,2012,38(5):505-514.
[15] He H, Zhu MT.Progress of ADR monitoring in China[J]. Journal of liaoning university of chinese medicine(辽宁中医药大学学报), 2018,20(6):142-145.
[16] Xiong R, Yin T, Duan CY, et al.Clinical observation of appatinib combined with systemic chemotherapy for liver metastasis of gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Pharmacy(中国药房),2019,30(6):821-824.
[17] Zhang M, Shi XD, Zhao P, et al.Analysis of clinicopathologic features, diagnosis and treatment of 405 cases with gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Journal of Digestion(中华消化杂志),2016,36(12):816-821.
[18] Wang FX, Shen QH, Fan GB, et al.Analysis of 190 cases of ADR reports in our hospital[J]. Chinese Pharmacy(中国药房), 2015,26(5):641-643.
[19] Huang L, Ma Z.The main adverse reactions and countermeasures of molecular targeted anti-tumor drugs[J]. Journal of Hubei University of Science and Technology (Medical Edition)[湖北科技学院学报(医学版)], 2018,32(6):545-549.
[20] Li D.Status quo of adverse reactions of 128 anti-tumor drugs[J]. China Medical Engineering(中国医学工程), 2019,27(3):102-104.
[21] Wang NN, Bai Y, Liu H, et al.Characteristics of adverse reactions of antineoplastic drugs in 787 cases and the prognosis analysis[J]. Anti-Tumor Pharmacy(肿瘤药学), 2019,9(1):143-148.
[22] Zhang Y.The manifestations and prevention and treatment of skin adverse reactions with EGFRI of targeted antitumor drugs[J]. Electronic Journal of Integrated Chinese and Western Medicine for Cardiovascular diseases(中西医结合心血管病电子杂志), 2018,6(27):198.
[23] Huang CL, Guo DH, Zhu M, et al.Analysis on 9819 cases of ADR/ADE associated with quinolones in military hospitals[J]. Drug application and monitoring in China(中国药物应用与监测), 2017, 14(5):293-296.
[24] Tian CH.Thinking to promote adverse drug reaction monito-ring work of medical institutions[J]. Chinese Journal of Pharma-covigilance(中国药物警戒) ,2016,13(5): 272-274.
[25] Ding PN,Lord SJ,Gebski V,et al.Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, and afatinib in advanced EGFR-mutated non-small gell lung cancer[J]. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer,2017,12(4): 633-643.
[26] Chen XQ, Jin YY, Tang G. Modern Pharmacology (新编药物学)[M]. Beijing: People's Medical Publishing House, 2011:17.

抗肿瘤靶向药品不良反应主动监测分析

Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.